{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:49:05Z","timestamp":1794019745111,"version":"4.8.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100016062","name":"National Health Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016175","name":"Chulabhorn Royal Academy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016175","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Public Health"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.jiph.2024.03.030","type":"journal-article","created":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T07:40:22Z","timestamp":1711698022000},"page":"897-905","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["A randomized trial to assess the acceleration of viral clearance by the combination Favipiravir\/Ivermectin\/Niclosamide in mild-to-moderate COVID-19 adult patients (FINCOV)"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7256-9982","authenticated-orcid":false,"given":"Taweegrit","family":"Siripongboonsitti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kriangkrai","family":"Tawinprai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panisadee","family":"Avirutnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunlakanya","family":"Jitobaom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4745-4291","authenticated-orcid":false,"given":"Prasert","family":"Auewarakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.jiph.2024.03.030_bib1","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jiph.2024.03.030_bib2","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of Covid-19 in Nonhospitalized Patients","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiph.2024.03.030_bib3","unstructured":"U.S. Food and Drug Administration, FDA NEWS RELEASE, Coronavirus (COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19 2021 [updated December 22, 2021. Available from: \u3008https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19\u3009]."},{"issue":"2","key":"10.1016\/j.jiph.2024.03.030_bib4","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/cpt.1844","article-title":"Favipiravir: pharmacokinetics and concerns about clinical trials for 2019\u2010nCoV infection","volume":"108","author":"Du","year":"2020","journal-title":"Clin Pharm Ther"},{"issue":"7","key":"10.1016\/j.jiph.2024.03.030_bib5","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc Jpn Acad, Ser B"},{"issue":"10","key":"10.1016\/j.jiph.2024.03.030_bib6","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.eng.2020.03.007","article-title":"Experimental treatment with favipiravir for COVID-19: an open-label control study","volume":"6","author":"Cai","year":"2020","journal-title":"Engineering"},{"key":"10.1016\/j.jiph.2024.03.030_bib7","article-title":"Favipiravir versus arbidol for COVID-19: a randomized clinical trial","author":"Chen","year":"2020","journal-title":"MedRxiv"},{"key":"10.1016\/j.jiph.2024.03.030_bib8","article-title":"AVIFAVIR for treatment of patients with moderate coronavirus disease 2019 (COVID-19): interim results of a phase II\/III multicenter randomized clinical trial","author":"Ivashchenko","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiph.2024.03.030_bib9","unstructured":"Department of Medical Service. Clinical Practice Guideline to Diagnosis, Treatment and Prevention COVID-19 for Physician and Health Care Provider, 21 July 2021 [Available from: https:\/\/covid19.dms.go.th\/Content\/Select_Landding_page?contentId=139]."},{"key":"10.1016\/j.jiph.2024.03.030_bib10","article-title":"Role of favipiravir in the treatment of COVID-19","author":"Joshi","year":"2020","journal-title":"Inter J Infect Dis"},{"key":"10.1016\/j.jiph.2024.03.030_bib11","article-title":"Fujita Health University","volume":"3","author":"Doi","year":"2021","journal-title":"Favipiravir Obs Study Interim Rep"},{"key":"10.1016\/j.jiph.2024.03.030_bib12","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijid.2020.11.142","article-title":"Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial","volume":"103","author":"Udwadia","year":"2021","journal-title":"Inter J Infect Dis"},{"issue":"6","key":"10.1016\/j.jiph.2024.03.030_bib13","article-title":"The real-world clinical outcomes of favipiravir treatment with telemedicine monitoring in preventing disease progression in mild to moderate COVID-19 patients: a retrospective cohort study","volume":"59","author":"Siripongboonsitti","year":"2023","journal-title":"Med (Kaunas)"},{"issue":"1","key":"10.1016\/j.jiph.2024.03.030_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-42195-x","article-title":"Favipiravir treatment in non-severe COVID-19: promising results from multicenter propensity score-matched study (FAVICOV)","volume":"13","author":"Siripongboonsitti","year":"2023","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.jiph.2024.03.030_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-90551-6","article-title":"The efficacy and safety of Favipiravir in treatment of COVID-19: A systematic review and meta-analysis of clinical trials","volume":"11","author":"Hassanipour","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.jiph.2024.03.030_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12985-020-01412-z","article-title":"Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis","volume":"17","author":"Shrestha","year":"2020","journal-title":"Virol J"},{"key":"10.1016\/j.jiph.2024.03.030_bib17","article-title":"Favipiravir in patients with early mild-to-moderate COVID-19: a randomized controlled trial","author":"Golan","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.jiph.2024.03.030_bib18","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1002\/psp4.12685","article-title":"Population pharmacokinetics of favipiravir in patients with COVID-19","volume":"10","author":"Irie","year":"2021","journal-title":"CPT Pharmacomet Syst Pharm"},{"key":"10.1016\/j.jiph.2024.03.030_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antivir Res"},{"issue":"18","key":"10.1016\/j.jiph.2024.03.030_bib20","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1056\/NEJMoa2115869","article-title":"Effect of early treatment with ivermectin among patients with COVID-19","volume":"386","author":"Reis","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jiph.2024.03.030_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106516","article-title":"High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial","volume":"59","author":"Buonfrate","year":"2022","journal-title":"Int J Antimicrob Agents"},{"issue":"12","key":"10.1016\/j.jiph.2024.03.030_bib22","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/j.jiac.2021.08.021","article-title":"Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): a single-centre randomized, placebo-controlled trial","volume":"27","author":"Mohan","year":"2021","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiph.2024.03.030_bib23","doi-asserted-by":"crossref","first-page":"343","DOI":"10.18433\/jpps32105","article-title":"Evaluation of ivermectin as a potential treatment for mild to moderate COVID-19: a double-blind randomized placebo controlled trial in Eastern India","volume":"24","author":"Ravikirti","year":"2021","journal-title":"J Pharm Pharm Sci"},{"issue":"11","key":"10.1016\/j.jiph.2024.03.030_bib24","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jama.2023.1650","article-title":"Effect of higher-dose ivermectin for 6 days vs placebo on time to sustained recovery in outpatients with COVID-19: A randomized clinical trial","volume":"329","author":"Naggie","year":"2023","journal-title":"JAMA"},{"issue":"16","key":"10.1016\/j.jiph.2024.03.030_bib25","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1001\/jama.2022.18590","article-title":"Effect of ivermectin vs placebo on time to sustained recovery in outpatients with mild to moderate COVID-19: A randomized clinical trial","volume":"328","author":"Naggie","year":"2022","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.jiph.2024.03.030_bib26","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/20477724.2021.1890887","article-title":"Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection","volume":"115","author":"Galan","year":"2021","journal-title":"Pathog Glob Health"},{"issue":"10","key":"10.1016\/j.jiph.2024.03.030_bib27","doi-asserted-by":"crossref","first-page":"5833","DOI":"10.1002\/jmv.27122","article-title":"Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: a randomized controlled study","volume":"93","author":"Abd-Elsalam","year":"2021","journal-title":"J Med Virol"},{"issue":"4","key":"10.1016\/j.jiph.2024.03.030_bib28","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1001\/jamainternmed.2022.0189","article-title":"Efficacy of ivermectin treatment on disease progression among adults with mild to moderate COVID-19 and comorbidities: The I-TECH randomized clinical trial","volume":"182","author":"Lim","year":"2022","journal-title":"JAMA Intern Med"},{"issue":"1","key":"10.1016\/j.jiph.2024.03.030_bib29","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1186\/s12879-021-06348-5","article-title":"Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial","volume":"21","author":"Vallejos","year":"2021","journal-title":"BMC Infect Dis"},{"issue":"14","key":"10.1016\/j.jiph.2024.03.030_bib30","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1001\/jama.2021.3071","article-title":"Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial","volume":"325","author":"L\u00f3pez-Medina","year":"2021","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.jiph.2024.03.030_bib31","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2201662","article-title":"Randomized trial of metformin, ivermectin, and fluvoxamine for COVID-19","volume":"387","author":"Bramante","year":"2022","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.jiph.2024.03.030_bib32","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1111\/bph.15843","article-title":"Niclosamide-a promising treatment for COVID-19","volume":"179","author":"Singh","year":"2022","journal-title":"Br J Pharm"},{"issue":"7","key":"10.1016\/j.jiph.2024.03.030_bib33","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00819-20","article-title":"Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs","volume":"64","author":"Jeon","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.jiph.2024.03.030_bib34","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.44942","article-title":"Efficacy of niclosamide vs placebo in sars-cov-2 respiratory viral clearance, viral shedding, and duration of symptoms among patients with mild to moderate COVID-19: A phase 2 randomized clinical trial","volume":"5","author":"Cairns","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jiph.2024.03.030_bib35","article-title":"A randomised controlled trial of effectiveness and safety of Niclosamide as add on therapy to the standard of care measures in COVID-19 management","volume":"69","author":"Abdulamir","year":"2021","journal-title":"Ann Med Surg (Lond)"},{"issue":"1","key":"10.1016\/j.jiph.2024.03.030_bib36","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s40360-022-00580-8","article-title":"Synergistic anti-SARS-CoV-2 activity of repurposed anti-parasitic drug combinations","volume":"23","author":"Jitobaom","year":"2022","journal-title":"BMC Pharm Toxicol"},{"key":"10.1016\/j.jiph.2024.03.030_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/av.2023.12265","article-title":"Favipiravir and ivermectin show in vitro synergistic antiviral activity against SARS-CoV-2","volume":"67","author":"Jitobaom","year":"2023","journal-title":"Acta Virol"},{"key":"10.1016\/j.jiph.2024.03.030_bib38","unstructured":"European Medicines Agency, ICH: E6 (R2) Good Clinical Practice\u2013Scientific Guideline. 2016."},{"key":"10.1016\/j.jiph.2024.03.030_bib39","unstructured":"WHO, Health in all policies: Helsinki statement. Framework for country action. Health in all Policies Helsinki Statement Framework for Country Action. 2014."},{"issue":"8","key":"10.1016\/j.jiph.2024.03.030_bib40","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1016\/S1473-3099(20)30483-7","article-title":"A minimal common outcome measure set for COVID-19 clinical research","volume":"20","author":"Marshall","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jiph.2024.03.030_bib41","unstructured":"COVID-19 Treatment Guidelines Panel, Coronavirus Disease 2019 (COVID-19) Treatment Guidelines 2020 [19 November 2022]. Available from: \u3008https:\/\/www.covid19treatmentguidelines.nih.gov\/\u3009."},{"key":"10.1016\/j.jiph.2024.03.030_bib42","article-title":"Infectious diseases society of america guidelines on the treatment and management of patients with COVID-19","author":"Bhimraj","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.jiph.2024.03.030_bib43","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00192-22","article-title":"Characterizing SARS-CoV-2 viral clearance kinetics to improve the design of antiviral pharmacometric studies","volume":"66","author":"Watson","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.jiph.2024.03.030_bib44","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1586\/ecp.13.6","article-title":"Applications of pharmacometrics in the clinical development and pharmacotherapy of anti-infectives","volume":"6","author":"Trivedi","year":"2013","journal-title":"Expert Rev Clin Pharm"},{"key":"10.1016\/j.jiph.2024.03.030_bib45","unstructured":"Watson J.A., Kisslerc S., Daya N.P., Gradc Y., Whitea N.J. Optimal design for phase 2 studies of SARS-CoV-2 antiviral drugs. MedRxiv 2021."},{"issue":"3","key":"10.1016\/j.jiph.2024.03.030_bib46","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/bcp.14476","article-title":"Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID-19","volume":"87","author":"Pe\u00f1a-Silva","year":"2021","journal-title":"Br J Clin Pharm"},{"issue":"5","key":"10.1016\/j.jiph.2024.03.030_bib47","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/BF01839186","article-title":"The effect of protein binding on ivermectin uptake by bovine brain microvessel endothelial cells","volume":"16","author":"Audus","year":"1992","journal-title":"Vet Res Commun"},{"key":"10.1016\/j.jiph.2024.03.030_bib48","article-title":"A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: a broad spectrum antiviral candidate for treatment of COVID-19","volume":"4","author":"Backer","year":"2021","journal-title":"Lancet Reg Health Eur"},{"issue":"2","key":"10.1016\/j.jiph.2024.03.030_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0246803","article-title":"Development and evaluation of inhalable composite niclosamide-lysozyme particles: a broad-spectrum, patient-adaptable treatment for coronavirus infections and sequalae","volume":"16","author":"Brunaugh","year":"2021","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.jiph.2024.03.030_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0198389","article-title":"A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer","volume":"13","author":"Schweizer","year":"2018","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.jiph.2024.03.030_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0202709","article-title":"Correction: a phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer","volume":"13","author":"Schweizer","year":"2018","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.jiph.2024.03.030_bib52","doi-asserted-by":"crossref","first-page":"8195","DOI":"10.1007\/s11033-021-06770-7","article-title":"Niclosamide for Covid-19: bridging the gap","volume":"48","author":"Al-Kuraishy","year":"2021","journal-title":"Mol Biol Rep"}],"container-title":["Journal of Infection and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034124001060?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034124001060?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T12:14:47Z","timestamp":1714306487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876034124001060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1876034124001060"],"URL":"https:\/\/doi.org\/10.1016\/j.jiph.2024.03.030","relation":{},"ISSN":["1876-0341"],"issn-type":[{"value":"1876-0341","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized trial to assess the acceleration of viral clearance by the combination Favipiravir\/Ivermectin\/Niclosamide in mild-to-moderate COVID-19 adult patients (FINCOV)","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiph.2024.03.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.","name":"copyright","label":"Copyright"}]}}